Edition:
United Kingdom

MiMedx Group Inc (MDXG.OQ)

MDXG.OQ on NASDAQ Stock Exchange Capital Market

3.74USD
20 Jul 2018
Change (% chg)

$-0.28 (-6.97%)
Prev Close
$4.02
Open
$4.13
Day's High
$4.22
Day's Low
$3.68
Volume
1,150,293
Avg. Vol
861,976
52-wk High
$18.24
52-wk Low
$3.01

Select another date:

Thu, Jun 7 2018

MiMedx to restate financial statements, replaces CFO

Biotech firm MiMedx Group Inc replaced its chief financial officer on Thursday and said it would restate at least five years of financial statements following an internal investigation into sales and distribution practices, sending shares down as much as 30 percent.

UPDATE 3-MiMedx to restate financial statements, replaces CFO

* Co restates statements from fiscal 2012-2016, 3 quarters in 2017

MiMedx to restate financial statements, appoints interim CFO

June 7 Biotech MiMedx Group Inc said on Thursday it plans to restate certain financial statements and appointed Edward Borkowski as its interim chief financial officer.

BRIEF-Mimedx Comments On Matters Related To Former Va Employees

* MIMEDX GROUP INC - COMMENTED ON INDICTMENT FILED IN COURT AGAINST INDIVIDUALS PREVIOUSLY EMPLOYED BY DEPARTMENT OF VETERANS AFFAIRS

U.S. indicts three veterans healthcare providers over MiMedx payments

Three healthcare providers with the U.S. Department of Veterans Affairs were indicted on charges they excessively used biotech MiMedx Group Inc's products on patients after accepting meals, trips and gratuities from the company.

U.S. indicts three veterans healthcare providers over MiMedx payments

May 9 Three healthcare providers with the U.S. Department of Veterans Affairs were indicted on charges they excessively used biotech MiMedx Group Inc's products on patients after accepting meals, trips and gratuities from the company.

BRIEF-MiMedx Sees Q2 Revenue $96 Million To $98 Million

* MIMEDX REPORTS UNREVIEWED FIRST QUARTER REVENUE EXCEEDED UPPER END OF ITS GUIDANCE

BRIEF-MiMedx Enrolls First Patient In Its Phase 2B Clinical Trial Of Amniofix® Injectable For Treatment Of Osteoarthritis Of The Knee

* MIMEDX ENROLLS FIRST PATIENT IN ITS PHASE 2B CLINICAL TRIAL OF RMAT DESIGNATED AMNIOFIX® INJECTABLE FOR THE TREATMENT OF OSTEOARTHRITIS OF THE KNEE Source text for Eikon: Further company coverage:

BRIEF-Mimedx Reports Positive Results From Phase 2B Clinical Trial Of Amniofix Injectable

* MIMEDX REPORTS POSITIVE PAIN AND FOOT FUNCTION RESULTS FROM PHASE 2B CLINICAL TRIAL OF AMNIOFIX® INJECTABLE IN THE TREATMENT OF PLANTAR FASCIITIS

BRIEF-MiMedx Says "Confident" in Q1 Rev Guidance, Discloses DoJ Investigation

* MIMEDX ANNOUNCES EXPECTATION TO EXCEED THE $92 MILLION TOP END OF FIRST QUARTER REVENUE GUIDANCE

Select another date: